Persistence of immune responses induced by Ebola virus vaccines.
The recent devastating outbreak of Ebola virus disease led to the accelerated development of multiple candidate vaccines against this virus, with at least eight entering clinical trials in 2014–16.1 Direct evidence of 100% eff ectiveness against disease has been demonstrated for VSV-EBOV, a vaccine...
| Main Author: | |
|---|---|
| Format: | Journal article |
| Published: |
Elsevier
2017
|
| Summary: | The recent devastating outbreak of Ebola virus disease led to the accelerated development of multiple candidate vaccines against this virus, with at least eight entering clinical trials in 2014–16.1 Direct evidence of 100% eff ectiveness against disease has been demonstrated for VSV-EBOV, a vaccine based on a replicating vesicular stomatitis virus genetically modifi ed to express Ebola virus glycoprotein.2 This vaccine has been granted Breakthrough Therapy Designation status by the US Food and Drug Administration and PRIME status by the European Medicines Agency, and its single-dose regimen and proof of eff ectiveness from 10 days postimmunisation make it an attractive candidate for use in a responsive campaign (whether it be through ring immunisation around identified cases or as a whole population intervention). |
|---|